Figure 6From: HSV-tk/GCV gene therapy mediated by EBV-LMP1 for EBV-associated cancerInhibition of nasopharyngeal carcinoma growth in athymic nude mice with pVLTR-tk/GCV treatment. Five mice per group were injected intratumorally every 24 hours for 7 days with GCV (100 μmg/g avoirdupois). The cancer growth was monitored every 2 days using calipers.Back to article page